Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02260505 2024-01-05

ImadGist

Phase 3 Completed

136 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01541709 2024-01-02

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Phase 2 Unknown

23 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04006769 2023-10-18

Entacapone Combination With Imatinib for Treatment of GIST

Phase EARLY_PHASE1 Completed

5 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1/2 Unknown

22 enrolled

Dermatologic

Melanoma

NCT05009927 2023-09-01

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Phase 2 Recruiting

50 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00161213 2023-08-14

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Phase 2 Completed

44 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00764595 2023-07-21

GISTs

Phase 2 Completed

5 enrolled

GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT05895942 2023-06-09

EMMBKM

Unknown

190 enrolled

Sarcoma

GIST

NCT00287105 2023-05-24

ESPHALL

Phase 2 Completed

49 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00667953 2023-03-30

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase 1/2 Terminated

32 enrolled 8 charts

Dermatologic

Melanoma

NCT00323063 2023-03-29

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Phase 2 Terminated

49 enrolled 11 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

O-Mel-Inib

PALANGI3

Imatinib TDM in GIST

LAMP-2

ATEZOGIST

TOKIN

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

TIPI

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

ALL Adult Consortium Trial: Adult ALL Trial

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

UKALL14

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

MATRIX-Rare

DESTINY

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

CMLXI

Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM

PLATFORM Study of Precision Medicine for Rare Tumors

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

SPRING

K2SPIRIT

Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

PInNACLe

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

ImadGist

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Entacapone Combination With Imatinib for Treatment of GIST

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

GISTs

EMMBKM

ESPHALL

Study of Temzolomide and Gleevec in Advanced Melanoma

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer